XIX International AIDS Conference

Efficacy and safety results from a randomized, double blind, active controlled trial of elvitegravir (once-daily) versus raltegravir (twice-daily) in treatment-experienced HIV-positive patients: long term 96-week data TUAB0105

Time: 12:05
Speaker: Richard Elion

This text willreplaced

You can download the video file here

For more information on this presentation, including access to speaker presentations, please see the conference Programme-at-a-Glance page.

Contact Us | Site map © 2012 International AIDS Society